LACTBL1 Inhibitors
LACTBL1 Inhibitors encompass a collection of chemical compounds that interfere with cellular processes and signaling pathways, leading to the indirect inhibition of LACTBL1's activity. For instance, Roscovitine and PD 0332991, as selective CDK inhibitors, hinder cell cycle progression, a process in which LACTBL1 is likely involved, thereby reducing its functional activity. Similarly, the NUAK1 inhibitor WZ4003 and RAF kinase inhibitors GW 5074 and ZM 336372 could disrupt kinase signaling interactions that are essential for LACTBL1's role, leading to decreased LACTBL1 activity. mTOR signaling, pivotal for metabolic processes where LACTBL1 may be implicated, can be dampened by Rapamycin, resulting in an indirect diminution of LACTBL1's metabolic functions. Also, the NEDD8-activating enzyme inhibition by MLN 4924 may affect LACTBL1 by impeding protein metabolic processes essential for its function. The PI3K signaling pathway, a hub for numerous cellular functions, is targeted by LY 294002, and its inhibition could lead to decreased LACTBL1 activity by affecting metabolic signaling pathways that LACTBL1 may influence.
Moreover, the inhibition of DNA damage repair pathways by Olaparib could potentially reduce LACTBL1's activity related to these processes, while the Aurora kinase A inhibitor Alisertib could diminish LACTBL1's function by disrupting mitotic events. The targeting of the Wnt signaling pathway by IWP-2 also suggests a decrease in LACTBL1 activity if LACTBL1 is involved in Wnt-related cellular processes. Lastly, the inhibition of p38 MAPK by SB 203580 could lead to a diminished LACTBL1 function by downregulating stress and inflammation responses where LACTBL1 may play a role. Collectively, these LACTBL1 inhibitors exert their effects through specific biochemical pathways, leading to a comprehensive decrease in the functional activity of LACTBL1 without affecting its expression directly.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine is a selective inhibitor of cyclin-dependent kinases (CDKs). Since LACTBL1 has been implicated in cell cycle regulation, the inhibition of specific CDKs by Roscovitine could diminish the functional activity of LACTBL1 by disrupting the cell cycle progression where LACTBL1 plays a role. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 is a potent and selective inhibitor of the NUAK family, including NUAK1. Given that LACTBL1 may interact with kinases for its function, WZ4003, by inhibiting NUAK1, could indirectly decrease the functional activity of LACTBL1 through these interactions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, and since LACTBL1 has been associated with metabolic processes regulated by mTOR signaling, this compound could indirectly inhibit the protein by diminishing the metabolic pathways necessary for its function. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
As a PARP inhibitor, Olaparib may indirectly inhibit LACTBL1 by impairing DNA damage repair pathways where LACTBL1 is potentially involved, thus reducing its functional activity related to these processes. | ||||||
PD 0332991 Isethionate | 827022-33-3 | sc-478943 | 1 mg | $300.00 | ||
PD 0332991, also known as Palbociclib, is a CDK4/6 inhibitor. By disrupting the cell cycle regulation in which LACTBL1 might be implicated, this inhibitor could lead to a decrease in LACTBL1 activity by halting cell cycle-dependent processes. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN 4924 is a NEDD8-activating enzyme inhibitor, which by inhibiting neddylation can affect protein turnover and function. As LACTBL1 is involved in protein metabolic processes, inhibiting neddylation could diminish the functional activity of LACTBL1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor. PI3K signaling is crucial for many cellular processes, including those related to metabolism where LACTBL1 might play a role. Inhibiting this pathway could lead to a decrease in LACTBL1 functional activity by affecting metabolic signaling. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW 5074 is a RAF kinase inhibitor. Since LACTBL1 may be involved in signaling pathways that include RAF, inhibiting this kinase could lead to diminished LACTBL1 activity by altering downstream signaling. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
IWP-2 is an inhibitor of Wnt processing and secretion. Although Wnt proteins are not direct targets, by inhibiting Wnt signaling, IWP-2 could potentially decrease LACTBL1 activity if LACTBL1 is involved in Wnt pathway-related processes. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM 336372 is a potent inhibitor of CRAF and BRAF kinases. If LACTBL1 activity is linked to RAF signaling, the inhibition of these kinases could indirectly diminish the functional activity of LACTBL1 by affecting the signaling pathways it is implicated in. | ||||||